| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453707 | Lung Cancer | 2018 | 9 Pages |
Abstract
The efficacy and safety of nivolumab in Korean patients with advanced or recurrent squamous or non-squamous NSCLC are consistent with previous reports.
Keywords
EGFRNivolumabTKIPD-1ORRPD-L1ALTECoGPFsASTAspartate aminotransferaseAlanine aminotransferaseALKprogression-free survivaloverall survivalstable diseaseprogressive diseaseRECISTNon-small-cell lung cancerNSCLCNon-small cell lung cancereastern cooperative oncology groupadverse eventconfidence intervalAnaplastic lymphoma kinaseProgrammed death-1Programmed cell death-1Response Evaluation Criteria in Solid TumorsTyrosine kinase inhibitorobjective response ratehazard ratioPartial responseObjective responsecomplete responseEpidermal growth factor receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jong Seok Lee, Ki Hyeong Lee, Eun Kyung Cho, Dong-Wan Kim, Sang-We Kim, Joo-Hang Kim, Byoung Chul Cho, Jin Hyoung Kang, Ji-Youn Han, Young Joo Min, Keunchil Park,